Initiate the Phase 3 program in scalp psoriasis
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- August 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects to initiate its Phase 3 program in scalp psoriasis in the second half of 2021”
What we found
Evidence strength A What the grades mean
A February 2022 8-K says the company announced in August 2021 that it had initiated a pivotal Phase 3 scalp and body psoriasis trial, within the second half of 2021 deadline.
-
A Arcutis Biotherapeutics, Inc. 8-K filed 2022-02-22
“In August 2021, Arcutis announced the initiation of a single pivotal Phase 3 trial for the treatment of scalp and body psoriasis, with topline data anticipated in the second half of 2022.” ✓ confirmed on the page
-
A Arcutis Biotherapeutics, Inc. 10-K filed 2022-02-22
“We also initiated a single pivotal Phase 3 clinical trial in scalp and body psoriasis indications, with topline data anticipated in the second half of 2022.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Phase 3 program in scalp psoriasis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: Pending discussions with regulators
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Arcutis Biotherapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ARQT-023951 · Corrections policy